All News
Can we find Axial Spa (FaxSpa) using social media? This study used an online screening tool (A-tool) on social media in patients with back pain. 42% had a positive screen and referred for review @RheumNow #ACR20 Abstr#1894
Dr. Antoni Chan synovialjoints ( View Tweet)
#ACR20 Abs#L11. Efficacy of TOFA vs PBO in AS. At week 16, %ASAS20 responders 56% v 29% PBO; %ASAS40 40% vs 12%. @RheumNow #ACRBest https://t.co/3Faj64rBjd
Eric Dein ejdein1 ( View Tweet)
Gender disparity in Ankylosing Spondylitis symptoms.
1⃣Women ⬆️Achilles tendonitis, plantar fasciitis, joint swelling, BASDAI>40, DMARD use
2⃣HLA-B not associated w/ enthesitis
@RheumNow #ACR20 Abs#1872 https://t.co/bxiNUjY1Xh
Robert B Chao, MD doctorRBC ( View Tweet)
Study out of China, #ABS1892 shows that patient reported outcomes using self assessments are important in AS T2T and decreasing flare rates #ACR20 @RheumNow. https://t.co/ebGtVUg8IV https://t.co/oXvGxQSjtn
Dr. Rachel Tate uptoTate ( View Tweet)
Do you routinely request for HLA-B27 in young patients w/ IBP? @RheumNow #ACR20
sheila RHEUMarampa ( View Tweet)
Do you take into account the location of bone marrow edema in the SI joint of a pt w/ inflammatory back pain when trying to determine if a pt has SpA? Check out Abst1535 at #ACR20 for more thoughts on this. @RheumNow @ElaineHusniMD
Meral K. El Ramahi, MD MeralElRamahiMD ( View Tweet)
~1/3 early RA patients report unacceptable pain w/in one year of diagnosis. 69% have pain w/ low inflammation. No objective baseline measures predict unacceptable pain. #ACR20 @RheumNow Abs#1716 We need to start pain approaches at time of diagnosis for all
Eric Dein ejdein1 ( View Tweet)
Pulmonary disease and glucocorticoid usage risk factors for RA medication changes in first 3 month of #COVID19. Pts with higher reported disease activity more likely to make Rx changes #ACR20 @RheumNow. Abst#L05.
Eric Dein ejdein1 ( View Tweet)
My axSpA patients often ask me whether whether it's the weight loss that matters, or just exercise.
Some answers from @rheum_cat - BMI itself does matter in AS. Another one chalked up for the obesity-related inflammasome!
#ACR20 ABST1883 @RheumNow https://t.co/oMOqA8ypTt
David Liew drdavidliew ( View Tweet)
Lots of interesting studies in Spondyloarthritis including AxSpA and PsA at #ACR20 @RheumNow https://t.co/tIyqyMdmTf
Dr. Antoni Chan synovialjoints ( View Tweet)
When discussing pregnancy outcomes with your axSpA patients, do you address potential outcomes related to disease in addition to medication concerns? #ACR20 @RheumNow
Dr. Rachel Tate uptoTate ( View Tweet)
Watch my interview with Dr Sinead Maguire @Sineadm15 on her SLR and meta-analysis on pregnancy in AxSpA presented at #ACR20 abstr#1323 @rheumnow @bososhea @FionaWilsonf @tomkodwyer https://t.co/E58rhIUZA4
Richard Conway RichardPAConway ( View Tweet)
Adverse pregnancy outcomes risk factors in spondyloarthritis
1⃣Most common - GSA
2⃣IBD symptoms, aggressive/active disease ⬆️risk
3⃣No difference in age or steroid use
Healthy mom, healthy baby.
@RheumNow #ACR20 Abs#1324
Robert B Chao, MD doctorRBC ( View Tweet)
Thinking of your last 20 consecutive Axial SpA patients in your clinic, which was the commonest extra-articular manifestation that you encountered? @RheumNow #ACR20 Abstr#1312
Dr. Antoni Chan synovialjoints ( View Tweet)
Are there distinct groups of axSpA and PsA patients with peripheral arthritis. This study shows heterogeneous patterns of peripheral involvement and overlap in SpA and PsA groups @RheumNow #ACR20 Abstr#1311 https://t.co/2Q5FH6ZrWm
Dr. Antoni Chan synovialjoints ( View Tweet)
Detection of inflammatory back pain (IBP) is important for the early diagnosis of Axial SpA. Which IBP criteria do you use in your clinic? @RheumNow #ACR20 Abst#1303
Dr. Antoni Chan synovialjoints ( View Tweet)
Pregnancy outcomes in women with AxSpA
4 prospective cohorts in Europe
328 total pregnancies
Favorable outcomes overall
1⃣3% pre-eclampsia
2⃣6-9% gestational DM
3⃣0-5% preterm birth rates (similar to WHO rate 9% in Eur)
@RheumNow #ACR20 Abs#1498
Robert B Chao, MD doctorRBC ( View Tweet)
Exploring new mode of action for treatment of AS. In BE AGILE study, Bimekizumab (BKZ) provides further sustained long-term improvements post 48 weeks in key efficacy outcome measures to 96 weeks of treatment @RheumNow #ACR20 Abstr#1364 https://t.co/972AvDNJDq
Dr. Antoni Chan synovialjoints ( View Tweet)
In the current era, would a positive treat-to-target study in AS change your approach to practice?
(TICOSPA trial ABST1444) #ACR20 @RheumNow
David Liew drdavidliew ( View Tweet)
Check out my video on T2T in SpA abstracts from #ACR20 @RheumNow https://t.co/ZBvmhWyDHU
Dr. Rachel Tate uptoTate ( View Tweet)
